

CITATION REPORT

List of articles citing

The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy)

DOI: 10.1016/j.jacc.2013.07.104

Journal of the American College of Cardiology, 2014, 63, 321-8.

Source: <https://exaly.com/paper-pdf/58675911/citation-report.pdf>

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
676	New oral anticoagulants in patients with nonvalvular atrial fibrillation: a review of pharmacokinetics, safety, efficacy, quality of life, and cost effectiveness. 2014 , 8, 789-98		80
675	Modern education, modern media: patient empowerment in today's medicine. 2014 , 111, 605-6		
674	Successful co-administration of dabigatran etexilate and protease inhibitors ritonavir/lopinavir in a patient with atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2014 , 112, 836-8	7	16
673	The target-specific oral anticoagulants: practical considerations. 2014 , 2014, 510-3		5
672	Laboratory tests during direct oral anticoagulant treatment?. 2014 , 9, 907-8		1
671	Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs. 2014 , 5, 109		34
670	New insights into treatment of venous thromboembolism. 2014 , 2014, 297-305		5
669	Monitoring target-specific oral anticoagulants. 2014 , 2014, 329-33		3
668	Preventive strategies against bleeding due to nonvitamin K antagonist oral anticoagulants. 2014 , 2014, 616405		4
667	Stroke prevention in patients with atrial fibrillation and renal dysfunction. 2014 , 45, 2497-505		12
666	Appropriateness of prescribing dabigatran etexilate and rivaroxaban in patients with nonvalvular atrial fibrillation: a prospective study. 2014 , 48, 1258-68		65
665	Bleeding complications of targeted oral anticoagulants: what is the risk?. 2014 , 2014, 504-9		5
664	A proposal for dose-adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin time. <i>British Journal of Clinical Pharmacology</i> , 2014 , 78, 599-609	3.8	21
663	Bleeding rates in Veterans Affairs patients with atrial fibrillation who switch from warfarin to dabigatran. 2014 , 127, 1179-85		42
662	Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays. 2014 , 12, 24		37
661	'New' direct oral anticoagulants in the perioperative setting. 2014 , 27, 409-19		35
660	Target-specific oral anticoagulants: practice issues for the clinician. 2014 , 42, 48-61		1


659	Regarding the effect of dabigatran plasma concentrations. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 2885	15.1	2
658	Reply: regarding the effect of dabigatran plasma concentrations. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 2885-6	15.1	3
657	A mouse bleeding model to study oral anticoagulants. <i>Thrombosis Research</i> , 2014 , 133 Suppl 1, S6-8	8.2	11
656	Rivaroxaban presents a better pharmacokinetic profile than dabigatran in an obese non-diabetic stroke patient. 2014 , 346, 366-7		26
655	Cardioembolic stroke in a patient taking Dabigatran Etxilate: the first case report of clinical and pharmacologic resistance. 2014 , 346, 348-9		7
654	Measurement of non-coumarin anticoagulants and their effects on tests of Haemostasis: Guidance from the British Committee for Standards in Haematology. 2014 , 166, 830-41		111
653	Knowing plasma concentrations improves management of the effects of dabigatran. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 847-8	15.1	
652	Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 1128-39	15.1	357
651	Global epidemiology of atrial fibrillation. 2014 , 11, 639-54		385
650	Dabigatran, bleeding, and the regulators. 2014 , 349, g4517		59
649	Dabigatran etexilate: a review of its use in the treatment of acute venous thromboembolism and prevention of venous thromboembolism recurrence. 2014 , 74, 1785-800		19
648	[New oral anticoagulants in perioperative medicine]. 2014 , 63, 347-62; quiz 363-4		12
647	Acute stroke in patients on new direct oral anticoagulants: how to manage, how to treat?. 2014 , 15, 1991-2001g		
646	Benefit-risk assessment of dabigatran in the treatment of stroke prevention in non-valvular atrial fibrillation. 2014 , 37, 295-307		2
645	Correlation between trough plasma dabigatran concentrations and estimates of glomerular filtration rate based on creatinine and cystatin C. 2014 , 14, 113-23		30
644	Identification of carboxylesterase-dependent dabigatran etexilate hydrolysis. 2014 , 42, 201-6		63
643	On the monitoring of dabigatran treatment in "real life" patients with atrial fibrillation. <i>Thrombosis Research</i> , 2014 , 134, 783-9	8.2	42
642	Thrombotic safety of prothrombin complex concentrate (Beriplex P/N) for dabigatran reversal in a rabbit model. <i>Thrombosis Research</i> , 2014 , 134, 729-36	8.2	23

641	Learning more from the dabigatran concentrations in the RE-LY study. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 2746-7	15.1	3
640	Coagulation assays and plasma fibrinogen concentrations in real-world patients with atrial fibrillation treated with dabigatran. <i>British Journal of Clinical Pharmacology</i> , 2014 , 78, 630-8	3.8	15
639	Potential antidotes for reversal of old and new oral anticoagulants. <i>Thrombosis Research</i> , 2014 , 133 Suppl 2, S158-66	8.2	35
638	Did minor flaws in a new drug reveal major flaws in company publication practices?. 2014 , 23, 132-133		
637	Practical advice on safe and effective use of non-vitamin K antagonist oral anticoagulants. 2015 , 1, 146-7		0
636	Monitoring and reversal of direct oral anticoagulants. 2015 , 2015, 117-24		41
635	Helsinki experience on nonvitamin K oral anticoagulants for treating cervical artery dissection. 2015 , 5, e00349		16
634	Real-world variability in dabigatran levels in patients with atrial fibrillation: comment. <i>Journal of Thrombosis and Haemostasis</i> , 2015 , 13, 1166-8	15.4	2
633	Real-world variability in dabigatran levels in patients with atrial fibrillation: reply. <i>Journal of Thrombosis and Haemostasis</i> , 2015 , 13, 1168-9	15.4	5
632	How to Avoid Adverse Events During Apixaban Therapy in Patients With Atrial Fibrillation. <i>Circulation Journal</i> , 2015 , 79, 2539-40	2.9	1
631	Closing the information gap between clinical and postmarketing trials: the case of dabigatran. 2015 , 1, 153-6		4
630	Dabigatran Concentration: Variability and Potential Bleeding Prediction In "Real-Life" Patients With Atrial Fibrillation. 2015 , 117, 323-9		28
629	The addition of idarucizumab to plasma samples containing dabigatran allows the use of routine coagulation assays for the diagnosis of hemostasis disorders. <i>Journal of Thrombosis and Haemostasis</i> , 2015 , 13, 2087-92	15.4	27
628	The new oral anticoagulants: clinical use and reversal agent development. 2015 , 10, 324-331		8
627	Hemodialysis for the treatment of dabigatran-associated bleeding: a case report and systematic review. <i>Journal of Thrombosis and Haemostasis</i> , 2015 , 13, 1790-8	15.4	48
626	Rivaroxaban and apixaban in orthopaedics: is there a difference in their plasma concentrations and anticoagulant effects?. 2015 , 26, 925-33		6
625	Clinical utility of dabigatran in United Arab Emirates. A pharmacovigilance study. 2015 , 36, 1290-8		2
624	Differential benefit risk assessment of DOACs in the treatment of venous thromboembolism: focus on dabigatran. 2015 , 9, 3557-69		

623	Current and emerging strategies in the management of venous thromboembolism: benefit-risk assessment of dabigatran. 2015 , 11, 271-82		6
622	Monitoring anticoagulant therapy with new oral agents. 2015 , 5, 212-5		10
621	Epidemiology, diagnosis, and management of atrial fibrillation in women. 2015 , 7, 605-14		23
620	[Non-VKA oral anticoagulants: an update for the clinical biologists]. 2015 , 73, 333-44		1
619	Non-VKA Oral Anticoagulants: Accurate Measurement of Plasma Drug Concentrations. 2015 , 2015, 345138		30
618	Estimation of dabigatran plasma concentrations in the perioperative setting. An ex vivo study using dedicated coagulation assays. <i>Thrombosis and Haemostasis</i> , 2015 , 113, 862-9	7	48
617	Novel oral anticoagulants and HIV: dabigatran use with antiretrovirals. 2015 , 2015,		18
616	Management of direct oral anticoagulants in the perioperative setting. 2015 , 29, 741-8		10
615	Use of Non-Vitamin K Antagonist Oral Anticoagulants in Special Patient Populations with Nonvalvular Atrial Fibrillation: A Review of the Literature and Application to Clinical Practice. 2015 , 75, 979-98		9
614	Dose tailoring of dabigatran etexilate: obvious or excessive?. 2015 , 14, 1283-9		19
613	A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. <i>Thrombosis and Haemostasis</i> , 2015 , 113, 943-51	7	205
612	Edoxaban and the need for outcomes-based NOAC dosing. 2015 , 385, 2232-3		3
611	Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran. <i>Thrombosis and Haemostasis</i> , 2015 , 114, 198-205	7	119
610	Oral anticoagulation: a critique of recent advances and controversies. 2015 , 36, 153-63		60
609	Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. 2015 , 385, 2288-95		275
608	Relationship between low Ankle-Brachial Index and rapid renal function decline in patients with atrial fibrillation: a prospective multicentre cohort study. 2015 , 5, e008026		17
607	Modified HAS-BLED Score and Risk of Major Bleeding in Patients Receiving Dabigatran and Rivaroxaban: A Retrospective, Case-Control Study. 2015 , 30, 395-402		5
606	New Oral Anticoagulants in Elderly Adults With Chronic Kidney Disease. 2015 , 90, 1587-9		2

605	Comparing Direct Oral Anticoagulants and Warfarin for Atrial Fibrillation, Venous Thromboembolism, and Mechanical Heart Valves. 2015 , 30, 644-56		7
604	Idarucizumab: The Antidote for Reversal of Dabigatran. 2015 , 132, 2412-22		125
603	Is Thrombin Time useful for the assessment of dabigatran concentrations? An in vitro and ex vivo study. <i>Thrombosis Research</i> , 2015 , 136, 693-6	8.2	24
602	Recent advances in atrial fibrillation and stroke. 2015 , 37, 381-4		1
601	Comparison of intermittent and continuous extracorporeal treatments for the enhanced elimination of dabigatran. 2015 , 53, 156-63		28
600	Dabigatran-Associated Intracranial Hemorrhage: Literature Review and Institutional Experience. 2015 , 5, 234-44		8
599	Editor-in-chief's picks from 2014: part two. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 701-375.1		
598	Changing practice of anticoagulation: will target-specific anticoagulants replace warfarin?. 2015 , 66, 241-53		18
597	Warfarin versus dabigatran etexilate: an assessment of efficacy and safety in patients with atrial fibrillation. 2015 , 14, 45-62		5
596	Real-world variability in dabigatran levels in patients with atrial fibrillation. <i>Journal of Thrombosis and Haemostasis</i> , 2015 , 13, 353-9	15.4	50
595	Recent advances in the development of specific antidotes for target-specific oral anticoagulants. 2015 , 35, 198-207		26
594	Monitoring and reversal strategies for new oral anticoagulants. 2015 , 13, 95-103		29
593	Antithrombotic therapy in 2014: Making headway in anticoagulant and antiplatelet therapy. 2015 , 12, 70-1		8
592	Non-vitamin K oral anticoagulants in atrial fibrillation: Where are we now?. 2015 , 25, 315-36		15
591	Effectiveness and safety of therapy with vitamin K antagonists in Italian patients aged 80 years or older: a multicentre retrospective study comparing the Zeus algorithm with the PARMA algorithm or manual therapy. 2015 , 32, 235-41		
590	The criteria of the Italian Federation of Thrombosis Centres on DOACs: a "real world" application in nonvalvular atrial fibrillation patients already on vitamin K antagonist. 2015 , 10, 157-63		8
589	To monitor dabigatran or not: a matter of patient safety. 2015 , 61, 691-3		6
588	Enhanced elimination of dabigatran through extracorporeal methods. 2015 , 11, 85-95		13

587	Regulatory, legislative, and policy updates with anticoagulant use. <i>Journal of Thrombosis and Thrombolysis</i> , 2015 , 39, 273-87	5.1	
586	New Oral Anticoagulants: How Do We Use Them Wisely?. 2015 , 17, 626		0
585	Clinical evaluation of laboratory methods to monitor apixaban treatment in patients with atrial fibrillation. <i>Thrombosis Research</i> , 2015 , 136, 148-53	8.2	46
584	From laboratory to clinical practice: Dabigatran effects on thrombin generation and coagulation in patient samples. <i>Thrombosis Research</i> , 2015 , 136, 154-60	8.2	16
583	Postinterventional use of dabigatran in patients undergoing ablation therapy using an accelerated loading dose scheme - a single center experience. <i>Thrombosis Research</i> , 2015 , 136, 486-7	8.2	1
582	Impact of dabigatran on platelet function and fibrinolysis. 2015 , 357, 204-8		7
581	Does the Russell Viper Venom time test provide a rapid estimation of the intensity of oral anticoagulation? A cohort study. <i>Thrombosis Research</i> , 2015 , 135, 852-60	8.2	23
580	Laboratory tests during direct oral anticoagulant treatment? Authors' reply. 2015 , 10, 533-4		
579	Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis. 2015 , 36, 3238-49		129
578	Idarucizumab for Dabigatran Reversal. 2015 , 373, 511-20		1223
577	Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. 2015 , 386, 680-90		269
576	Pros and cons of vitamin K antagonists and non-vitamin K antagonist oral anticoagulants. 2015 , 41, 178-87		22
575	Which patients may benefit from dose adjustment of non-vitamin K antagonist oral anticoagulants?. 2015 , 41, 195-207		15
574	Antithrombotic drugs, patient characteristics, and gastrointestinal bleeding: Clinical translation and areas of research. 2015 , 29, 335-43		18
573	[Oral anticoagulation for non-valvular atrial fibrillation in the elderly]. 2015 , 50, 134-42		5
572	Concomitant use of dronedarone with dabigatran in patients with atrial fibrillation in clinical practice. <i>Thrombosis Research</i> , 2015 , 135, 1070-4	8.2	13
571	Quality of oral anticoagulation with phenprocoumon in regular medical care and its potential for improvement in a telemedicine-based coagulation service--results from the prospective, multi-center, observational cohort study thrombEVAL. 2015 , 13, 14		31
570	Are new oral anticoagulant dosing recommendations optimal for all patients?. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 313, 1013-4	27.4	19

569	Analgesic use before and after oral anticoagulant initiation--a population-based study in Finland. <i>European Journal of Clinical Pharmacology</i> , 2015 , 71, 723-732	2.8	6
568	Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs. 2015 , 386, 303-10		97
567	Overview of the new oral anticoagulants: opportunities and challenges. 2015 , 35, 1056-65		124
566	Safety of new oral anticoagulants. 2015 , 350, h1679		5
565	The year in cardiology 2014: arrhythmias and device therapy. 2015 , 36, 270-8		4
564	Pharmacodynamic profile and drug interactions with non-vitamin K antagonist oral anticoagulants: implications for patients with atrial fibrillation. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015 , 11, 937-48	5.5	4
563	Anticoagulant therapy in atrial fibrillation: vitamin K antagonists or novel oral anticoagulant drugs?. 2015 , 16, 139-41		3
562	Type 2 diabetes mellitus and atrial fibrillation: From mechanisms to clinical practice. 2015 , 108, 269-76		77
561	Updates in the perioperative and emergency management of non-vitamin K antagonist oral anticoagulants. 2015 , 19, 203		51
560	Evaluating coagulation tests in patients with atrial fibrillation using direct oral anticoagulants. 2015 , 13, 1213-23		1
559	Sex Differences in Dabigatran Use, Safety, And Effectiveness In a Population-Based Cohort of Patients With Atrial Fibrillation. 2015 , 8, 593-9		45
558	Direct oral anticoagulants in atrial fibrillation: can data from randomized clinical trials be safely transferred to the general population? No. 2015 , 10, 647-50		8
557	Quality indicators as a tool in improving the introduction of new medicines. 2015 , 116, 146-57		16
556	Identification and management of noncompliance in atrial fibrillation patients receiving dabigatran: the role of a drug monitor. 2015 , 38, 465-71		9
555	Peri-procedural management of dabigatran and rivaroxaban: Duration of anticoagulant discontinuation and drug concentrations. <i>Thrombosis Research</i> , 2015 , 136, 763-8	8.2	31
554	The case for dosing dabigatran: how tailoring dose to patient renal function, weight and age could improve the benefit-risk ratio. 2015 , 8, 245-54		7
553	Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. <i>Europace</i> , 2015 , 17, 1467-507	3.9	803
552	Les anticoagulants oraux directs en 2015 chez le patient  : focus chez le sujet fragile. 2015 , 7, 122-137		

551	Dabigatran is Less Effective Than Warfarin at Attenuating Mechanical Heart Valve-Induced Thrombin Generation. 2015 , 4, e002322		60
550	Edoxaban for reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. 2015 , 16, 2661-78		2
549	Gastrointestinal bleeding in patients receiving oral anticoagulation: Current treatment and pharmacological perspectives. <i>Thrombosis Research</i> , 2015 , 136, 1074-81	8.2	21
548	CHA2DS2-VASc and HAS-BLED scores and activated partial thromboplastin time for prediction of high plasma concentration of dabigatran at trough. <i>Thrombosis Research</i> , 2015 , 135, 62-7	8.2	10
547	Monitoring of dabigatran therapy using Hemoclot(®) Thrombin Inhibitor assay in patients with atrial fibrillation. <i>Journal of Thrombosis and Thrombolysis</i> , 2015 , 39, 95-100	5.1	24
546	Correlation between rivaroxaban (Xarelto) plasma activity, patient clinical variables and outcomes in a South African centre. 2016 , 106, 1017-1020		4
545	THE PHARMACOKINETICS OF APIXABAN IN PATIENTS WITH CARDIOEMBOLIC STROKE IN ACUTE PHASE. <i>Rational Pharmacotherapy in Cardiology</i> , 2016 , 12, 253-259	0.5	1
544	Renal Function and Treatment Persistence with Non-Vitamin K Antagonist Oral Anticoagulants in Japanese Patients with Atrial Fibrillation: A Single-Center Experience. 2016 , 47, 115-122		1
543	Direct Oral Anticoagulants in Emergency Trauma Admissions. 2016 , 113, 575-82		20
542	Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran. 2016 , 10, 1683-9		8
541	The effect of dabigatran on the kaolin-activated whole blood thromboelastogram. 2016 , 44, 729-733		1
540	Measuring dabigatran with the dilute Russell viper venom confirm assay in an anticoagulation clinic population. 2016 , 27, 53-7		5
539	The assessment of anticoagulant activity to predict bleeding outcome in atrial fibrillation patients receiving dabigatran etexilate. 2016 , 27, 389-95		7
538	Laboratory measurement of the direct oral anticoagulants. 2016 , 172, 315-36		65
537	Idarucizumab for Dabigatran Reversal Guideline. 2016 , 15, 33-5		2
536	Reduced Anticoagulant Effect of Dabigatran in a Patient Receiving Concomitant Phenytoin. 2016 , 36, e5-7		27
535	Non-vitamin K Oral Anticoagulants Versus Warfarin for Patients with Atrial Fibrillation: Absolute Benefit and Harm Assessments Yield Novel Insights. 2016 , 34, 100-6		9
534	A single test to assay warfarin, dabigatran, rivaroxaban, apixaban, unfractionated heparin, and enoxaparin in plasma. <i>Journal of Thrombosis and Haemostasis</i> , 2016 , 14, 1043-53	15.4	8

533	Oral thrombin inhibitor aggravates platelet adhesion and aggregation during arterial thrombosis. 2016 , 8, 367ra168		27
532	What are the effects of edoxaban in the general population and in the elderly?. <i>European Heart Journal Supplements</i> , 2016 , 18, 113-117	1.5	
531	Reversal of direct oral anticoagulants: a practical approach. 2016 , 2016, 612-619		21
530	Los nuevos anticoagulantes orales. 2016 , 23, 541-549		
529	Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial. 2016 , 5,		144
528	Clinical evaluation of laboratory methods to monitor exposure of rivaroxaban at trough and peak in patients with atrial fibrillation. <i>European Journal of Clinical Pharmacology</i> , 2016 , 72, 671-9	2.8	18
527	Real Data on Effectiveness, Tolerability and Safety of New Oral Anticoagulant Agents: Focus on Dabigatran. 2016 , 23, 115-22		1
526	Direct oral anticoagulant drug level testing in clinical practice: A single institution experience. <i>Thrombosis Research</i> , 2016 , 143, 40-4	8.2	36
525	NOAC monitoring, reversal agents, and post-approval safety and effectiveness evaluation: A cardiac safety research consortium think tank. 2016 , 177, 74-86		34
524	Standard dose versus low dose non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation: A meta-analysis of contemporary randomized controlled trials. 2016 , 13, 2340-2347		23
523	Discontinuation and Management of Direct-Acting Anticoagulants for Emergency Procedures. 2016 , 129, S47-S53		14
522	Dabigatran etexilate activation is affected by the CES1 genetic polymorphism G143E (rs71647871) and gender. 2016 , 119, 76-84		41
521	Management issues of chronic therapy with non-vitamin K oral anticoagulants or antiplatelet agents: Different or alike?. 2016 , 221, 695-6		2
520	Direct Oral Anticoagulants: Monitoring Anticoagulant Effect. 2016 , 30, 995-1006		1
519	Hierarchical Models for Multiple, Rare Outcomes Using Massive Observational Healthcare Databases. 2016 , 9, 260-268		8
518	Estimated glomerular filtration rate calculated using different creatinine and cystatin based formulas in prediction of trough plasma Dabigatran concentration. 2016 , 463, 22-26		
517	Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjects. 2016 , 34, 26-32		26
516	Discontinuation and management of direct-acting anticoagulants for emergency procedures. 2016 , 34, 14-18		26

515	Dose response characterization of the association of serum digoxin concentration with mortality outcomes in the Digitalis Investigation Group trial. 2016 , 18, 1072-81		30
514	Pharmacogenetics of dabigatran etexilate interindividual variability. <i>Thrombosis Research</i> , 2016 , 144, 1-5	8.2	45
513	Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform study. <i>Journal of Thrombosis and Haemostasis</i> , 2016 , 14, 2194-2201	15.4	51
512	Reversal by the specific antidote, idarucizumab, of elevated dabigatran exposure in a patient with rectal perforation and paralytic ileus. 2016 , 117, 407-9		12
511	Direct Thrombin Inhibitors Prevent Left Atrial Remodeling Associated With Heart Failure in Rats. 2016 , 1, 328-339		22
510	Use of Direct Oral Anticoagulants in Special Populations. 2016 , 30, 1053-71		3
509	Upstream versus downstream thrombin inhibition. 2016 , 14, 1273-1282		3
508	Reduced dose and reduced exposure to non-vitamin K-antagonist oral anticoagulants: Some considerations on this relationship. 2016 , 223, 519-520		1
507	Factors influencing trough and 90-minute plasma dabigatran etexilate concentrations among patients with non-valvular atrial fibrillation. <i>Thrombosis Research</i> , 2016 , 145, 100-6	8.2	6
506	Idarucizumab for dabigatran reversal - Does one dose fit all?. <i>Thrombosis Research</i> , 2016 , 146, 103-104	8.2	22
505	Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for non-vitamin K antagonist oral anticoagulant dose adjustment. 2016 , 18, 1162-71		21
504	Measuring non-vitamin K antagonist oral anticoagulant levels: When is it appropriate and which methods should be used?. 2016 , 11, 748-58		33
503	Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects. 2016 , 129, S64-S72		28
502	Non-vitamin K antagonist oral anticoagulation usage according to age among patients with atrial fibrillation: Temporal trends 2011-2015 in Denmark. <i>Scientific Reports</i> , 2016 , 6, 31477	4.9	68
501	Glomerular filtration rate assessed by using creatinine and cystatin in patients treated with dabigatran. 2016 , 12, 243-248		1
500	Clinical Experience of Prescribing Dabigatran Etexilate With Dronedaron: The Role of Therapeutic Drug Monitoring. 2016 , 38, 813-814		7
499	Dosage Adjustment of Dabigatran Etexilate Based on Creatinine Clearance in Patients With Cardioembolic Stroke or Atrial Fibrillation. 2016 , 38, 670-676		4
498	Faster drug approval: challenges for safety. 2016 , 15, 1205-18		2

497	An open-label study of the pharmacokinetics and pharmacodynamics of dabigatran etexilate 150mg once daily in Caucasian patients with moderate renal impairment undergoing primary unilateral elective total knee or hip replacement surgery. <i>Thrombosis Research</i> , 2016 , 144, 158-64	8.2	4
496	The Effect of Cardiopulmonary Bypass on Dabigatran Levels. 2016 , 30, 1022-6		1
495	Idarucizumab for dabigatran overdose. 2016 , 54, 644-6		29
494	Evaluation of the chromogenic anti-factor IIa assay to assess dabigatran exposure in geriatric patients with atrial fibrillation in an outpatient setting. 2016 , 14, 10		9
493	Reversal agents for use with direct and indirect anticoagulants. 2016 , 73, S27-48		20
492	Evaluation of Dose-Reduced Direct Oral Anticoagulant Therapy. 2016 , 129, 1198-1204		101
491	Impact of Variations in Kidney Function on Nonvitamin K Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Recent Acute Heart Failure. 2016 , 69, 134-40		3
490	Evaluation of anticoagulant effects of direct thrombin inhibitors, dabigatran and argatroban, based on the Lineweaver-Burk plot applied to the Clauss assay. 2016 , 69, 370-2		5
489	Effect of standardized perioperative dabigatran interruption on the residual anticoagulation effect at the time of surgery or procedure. <i>Journal of Thrombosis and Haemostasis</i> , 2016 , 14, 89-97	15.4	32
488	Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2016 , 14, 1308-13	15.4	253
487	Determination of dabigatran and rivaroxaban by ultra-performance liquid chromatography-tandem mass spectrometry and coagulation assays after major orthopaedic surgery. <i>Thrombosis Research</i> , 2016 , 139, 128-34	8.2	25
486	Evaluation of a Heparin-Calibrated Antifactor Xa Assay for Measuring the Anticoagulant Effect of Oral Direct Xa Inhibitors. 2016 , 22, 423-8		35
485	[New oral anticoagulants for prophylaxis of stroke. Results of an expert conference on practical use in geriatric patients]. 2016 , 49, 216-26		2
484	Dabigatran Plasma Levels in Acute Cerebrovascular Events. 2016 , 25, 877-82		5
483	Plasma levels of direct oral anticoagulants in real life patients with atrial fibrillation: Results observed in four anticoagulation clinics. <i>Thrombosis Research</i> , 2016 , 137, 178-183	8.2	105
482	Repercusiones en la posología de los anticoagulantes orales no antagonistas de la vitamina K por las variaciones de la función renal de los pacientes con fibrilación auricular e insuficiencia cardíaca aguda reciente. 2016 , 69, 134-140		8
481	Novel oral anticoagulants in plastic surgery. 2016 , 69, 585-93		5
480	Reversal of novel oral anticoagulants. 2016 , 27, 86-91		12

479	Mass spectrometry in the therapeutic drug monitoring of direct oral anticoagulants. Useful or useless?. 2016 , 84, 41-50			12
478	Thrombin Generation Assay and Its Application in the Clinical Laboratory. 2016 , 62, 699-707			164
477	AOD : prudence d'utilisation chez le sujet âgé? Un propos d'un cas et revue de la littérature. 2016 , 28, 21-25			1
476	Reversal Agents for the New Generation of Oral Anticoagulants: Implications for the Perioperative Physician. 2016 , 30, 823-30			9
475	The challenges and limitations of widespread direct oral anticoagulant treatment: practical suggestions for their best use. 2016 , 14, 163-76			6
474	Laboratory measurement of the non-vitamin K antagonist oral anticoagulants: selecting the optimal assay based on drug, assay availability, and clinical indication. <i>Journal of Thrombosis and Thrombolysis</i> , 2016 , 41, 241-7	5.1		53
473	Stroke prevention using dabigatran in elderly Chinese patients with atrial fibrillation. 2016 , 13, 366-73			27
472	Reversal Strategies for NOACs: State of Development, Possible Clinical Applications and Future Perspectives. 2016 , 39, 5-13			18
471	Widening the path and window of opportunity for FDA approval of non-vitamin K oral anticoagulant specific antidotes and reversal agents. <i>Journal of Thrombosis and Thrombolysis</i> , 2016 , 41, 285-92	5.1		1
470	Rational Medical Therapy Is the Key to Effective Cardiovascular Disease Prevention. 2017 , 33, 626-634			2
469	New-onset atrial fibrillation after percutaneous coronary intervention with stent: Updated proposal of an algorithm for the choice of oral anticoagulant and its dose. 2017 , 40, e11-e12			4
468	Effect of dabigatran treatment at therapeutic levels on point-of-care international normalized ratio (INR). 2017 , 55, e143-e145			
467	Rotational thromboelastometry in ex vivo samples from routine clinical practice patients receiving dabigatran. 2017 , 466, 20-21			3
466	[Monitoring of NOAC]. 2017 , 112, 92-98			2
465	The risk of gastrointestinal bleeding in patients receiving dabigatran etexilate: a systematic review and meta-analysis of the literature. 2017 , 49, 329-342			5
464	Oral anticoagulant use in octogenarian European patients with atrial fibrillation: A subanalysis of PREFER in AF. 2017 , 232, 98-104			13
463	[Vitamin K antagonists : Is their prescription really "medical malpractice" today?]. 2017 , 58, 90-99			2
462	Corazón y anestesia: interferencias con los fármacos cardiovasculares. 2017 , 43, 1-8			

461	Risk of major bleeding and stroke associated with the use of vitamin K antagonists, nonvitamin K antagonist oral anticoagulants and aspirin in patients with atrial fibrillation: a cohort study. <i>British Journal of Clinical Pharmacology</i> , 2017 , 83, 1844-1859	3.8	17
460	Effects of dabigatran according to age in atrial fibrillation. 2017 , 103, 1015-1023		58
459	Ultrasound-guided fine-needle aspiration biopsy of thyroid nodules in patients on oral anticoagulants. 2017 , 40, 785-786		
458	Initiating and Managing Patients with Venous Thromboembolism on Anticoagulant Drugs: A Practical Overview. 2017 , 34, 3-10		
457	A Comparison of the Rate of Gastrointestinal Bleeding in Patients Taking Non-Vitamin K Antagonist Oral Anticoagulants or Warfarin. 2017 , 112, 734-739		28
456	Laboratory Assessment of Direct Oral Anticoagulants. 2017 , 43, 277-290		60
455	Oral Anticoagulant Use After Bariatric Surgery: A Literature Review and Clinical Guidance. 2017 , 130, 517-524		57
454	Dabigatran Etxilate: A Review in Nonvalvular Atrial Fibrillation. 2017 , 77, 331-344		12
453	Nicht-Vitamin-K-abhängige orale Antikoagulanzen. 2017 , 20, 251-264		
452	The recommended dose of idarucizumab may not always be sufficient for sustained reversal of dabigatran. <i>Journal of Thrombosis and Haemostasis</i> , 2017 , 15, 1317-1321	15.4	36
451	Management of Severe Bleeding in Patients Treated with Direct Oral Anticoagulants: An Observational Registry Analysis. 2017 , 127, 111-120		40
450	Dabigatran plasma levels, aPTT and thromboelastography in patients with AF: implications for allowing early non-elective surgical procedures. <i>Journal of Thrombosis and Thrombolysis</i> , 2017 , 44, 9-13	5.1	5
449	Coagulation Testing in Intracerebral Hemorrhage Related to Non-vitamin K Antagonist Oral Anticoagulants. 2017 , 27, 208-213		6
448	[Management of hemorrhage in patients treated with direct oral anticoagulants]. 2017 , 66, 679-689		2
447	A left atrial appendage thrombus that developed during prophylactic low-dose dabigatran treatment resolved after switching to apixaban. 2017 , 5, 711-713		9
446	Laboratory measurement of the direct oral anticoagulants: Indications and impact on management in clinical practice. 2017 , 39 Suppl 1, 31-36		21
445	Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation. <i>Journal of Thrombosis and Thrombolysis</i> , 2017 , 43, 365-379	5.1	62
444	Coagulation Testing in Acute Ischemic Stroke Patients Taking Non-Vitamin K Antagonist Oral Anticoagulants. 2017 , 48, 152-158		31

443	Atrial Fibrillation and Percutaneous Coronary Intervention. 2017 ,		
442	Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillation. 2017 , 189, E4-E10		34
441	Pharmacological management of pulmonary embolism. 2017 , 18, 79-93		3
440	Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin. <i>Journal of Thrombosis and Haemostasis</i> , 2017 , 15, 273-283	15.4	74
439	Dabigatran in nonvalvular atrial fibrillation: from clinical trials to real-life experience. 2017 , 18, 467-477		6
438	Cobicistat Versus Ritonavir: Similar Pharmacokinetic Enhancers But Some Important Differences. 2017 , 51, 1008-1022		66
437	Appropriate dosing of nonvitamin K antagonist oral anticoagulants for stroke prevention in atrial fibrillation. 2017 , 27, 567-572		4
436	Dabigatran reduces thrombin-induced platelet aggregation and activation in a dose-dependent manner. <i>Journal of Thrombosis and Thrombolysis</i> , 2017 , 44, 216-222	5.1	14
435	Novel (Oral) Anticoagulant Challenges in Surgery. 2017 , 43, 706-715		5
434	e-Health-based management of patients receiving oral anticoagulation therapy: results from the observational thrombEVAL study. <i>Journal of Thrombosis and Haemostasis</i> , 2017 , 15, 1375-1385	15.4	11
433	Cuore e anestesia: interferenze con i farmaci cardiovascolari. 2017 , 22, 1-8		
432	Whole blood coagulation assays ROTEM and T-TAS to monitor dabigatran treatment. <i>Thrombosis Research</i> , 2017 , 153, 76-82	8.2	25
431	Real life dabigatran and metabolite concentrations, focused on inter-patient variability and assay differences in patients with atrial fibrillation. 2017 , 55, 2002-2009		7
430	Successful use of laboratory monitoring to facilitate an invasive procedure for a patient treated with dabigatran. 2017 , 74, 461-465		5
429	Rapid and well tolerated action of idarucizumab for antagonizing dabigatran in a patient needing urgent thrombolysis: a case report. 2017 , 28, 576-579		13
428	Athletes and blood clots: individualized, intermittent anticoagulation management. <i>Journal of Thrombosis and Haemostasis</i> , 2017 , 15, 1051-1054	15.4	17
427	Increased risk of major bleeding in underweight patients with atrial fibrillation who were prescribed non-vitamin K antagonist oral anticoagulants. 2017 , 14, 501-507		43
426	Role of agents for reversing the effects of target-specific oral anticoagulants. 2017 , 74, 54-61		11

425	Massive Left Atrial Thrombi during Dabigatran Therapy for Nonvalvular Atrial Fibrillation. 2017 , 1, 198-201		4
424	Comparison of the ecarin chromogenic assay and diluted thrombin time for quantification of dabigatran concentrations. <i>Journal of Thrombosis and Haemostasis</i> , 2017 , 15, 2377-2387	15.4	15
423	Use of direct oral anticoagulants for treatment of atrial fibrillation in patients with HIV: a review. 2017 , 12, 554-560		11
422	Differential Influence of the Antiretroviral Pharmacokinetic Enhancers Ritonavir and Cobicistat on Intestinal P-Glycoprotein Transport and the Pharmacokinetic/Pharmacodynamic Disposition of Dabigatran. 2017 , 61,		28
421	A novel prothrombin time method to measure all non-vitamin K-dependent oral anticoagulants (NOACs). 2017 , 122, 171-176		1
420	Idarucizumab for the treatment of hemorrhage and dabigatran reversal in patients requiring urgent surgery or procedures. 2017 , 17, 1275-1296		9
419	Adherence with direct oral anticoagulants in nonvalvular atrial fibrillation new users and associated factors: a French nationwide cohort study. 2017 , 26, 1367-1377		36
418	Nicht-Vitamin-K-abhängige orale Antikoagulanzen. 2017 , 22, 585-599		
417	Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease. 2017 , 11, CD011373		47
416	Pharmacokinetics of dabigatran etexilate and rivaroxaban in patients with short bowel syndrome requiring parenteral nutrition: The PDER PAN study. <i>Thrombosis Research</i> , 2017 , 160, 76-82	8.2	10
415	Once- or twice-daily non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation: A meta-analysis of randomized controlled trials. 2017 , 116, 591-598		5
414	Development of an UHPLC-UV-Method for Quantification of Direct Oral Anticoagulants: Apixaban, Rivaroxaban, Dabigatran, and its Prodrug Dabigatran Etexilate in Human Serum. 2017 , 39, 66-76		14
413	[Procedures on patients receiving NOACs : What's possible?]. 2017 , 112, 117-124		1
412	Idarucizumab for Dabigatran Reversal - Full Cohort Analysis. 2017 , 377, 431-441		639
411	Non-vitamin K antagonist oral anticoagulants: impact of non-adherence and discontinuation. 2017 , 16, 1051-1062		13
410	Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses. 2017 , 39, 1456-1478.e36		81
409	An optimized dRVVT-based assay to estimate the intensity of anticoagulation in patients treated with direct oral anticoagulants. <i>Thrombosis Research</i> , 2017 , 157, 29-37	8.2	11
408	Prognostic Value of Red Blood Cell Distribution Width on Bleeding Events in Nonvalvular Atrial Fibrillation Patients Taking Dabigatran (110 mg b.i.d.) after Catheter Ablation. 2017 , 136, 215-221		3

407	The factor xa inhibitor edoxaban for the prevention of stroke and systemic embolism in patients with atrial fibrillation. 2017 , 10, 5-15		3
406	Feasibility of rapid measurement of Rivaroxaban plasma levels in patients with acute stroke. <i>Journal of Thrombosis and Thrombolysis</i> , 2017 , 43, 112-116	5.1	24
405	Letter in response to "Idarucizumab for dabigatran overdose". 2017 , 55, 65		1
404	Incidence of severe renal dysfunction among individuals taking warfarin and implications for non-vitamin K oral anticoagulants. 2017 , 184, 150-155		13
403	Measurement and reversal of the direct oral anticoagulants. 2017 , 31, 77-84		116
402	Apixaban-Calibrated Anti-FXa Activity in Relation to Outcome Events and Clinical Characteristics in Patients with Atrial Fibrillation: Results from the AVERROES Trial. <i>TH Open</i> , 2017 , 1, e139-e145	2.7	15
401	Assessment of the effect of direct oral anticoagulants dabigatran, rivaroxaban, and apixaban in healthy male volunteers using a thrombin generation assay. 2017 , 1, 194-201		24
400	Dose requirements for idarucizumab reversal of dabigatran in a lethal porcine trauma model with continuous bleeding. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 1370-1378	7	4
399	Safety, pharmacokinetics and pharmacodynamics of idarucizumab, a specific dabigatran reversal agent in healthy Japanese volunteers: a randomized study. 2017 , 1, 202-215		11
398	Practical guidance on the use of laboratory testing in the management of bleeding in patients receiving direct oral anticoagulants. 2017 , 13, 457-467		33
397	Recent advances in preventing stroke recurrence. 2017 , 6, 1017		6
396	Development of New Deep Venous Thrombosis While on Apixaban. 2017 , 2017, 2842935		4
395	Anticoagulation therapy in the elderly with non-valvular atrial fibrillation: a double-edged sword. 2017 , 3,		1
394	The Dose of Direct Oral Anticoagulants and Stroke Severity in Patients with Acute Ischemic Stroke and Nonvalvular Atrial Fibrillation. 2018 , 27, 1490-1496		11
393	Comprehensive characteristics of the anticoagulant activity of dabigatran in relation to its plasma concentration. <i>Thrombosis Research</i> , 2018 , 164, 32-39	8.2	13
392	Direct oral anticoagulant use and risk of perioperative bleeding: Evidence of absence or absence of evidence?. 2018 , 2, 182-185		6
391	Screening test for direct oral anticoagulants with the dilute Russell viper venom time. 2018 , 100, 567-574		8
390	Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis. 2018 , 39, 1672-1686f		59

389	GI Bleeding Risk of DOACs Versus Warfarin: Is Newer Better?. 2018 , 63, 1675-1677		9
388	Design and rationale for the DIVERSITY study: An open-label, randomized study of dabigatran etexilate for pediatric venous thromboembolism. 2018 , 2, 347-356		5
387	Targeting Coagulase Activity in Staphylococcus aureus Bacteraemia: A Randomized Controlled Single-Centre Trial of Staphylothrombin Inhibition. <i>Thrombosis and Haemostasis</i> , 2018 , 118, 818-829	7	10
386	Low drug levels and thrombotic complications in high-risk atrial fibrillation patients treated with direct oral anticoagulants. <i>Journal of Thrombosis and Haemostasis</i> , 2018 , 16, 842-848	15.4	74
385	Impact of BMI on clinical outcomes of NOAC therapy in daily care - Results of the prospective Dresden NOAC Registry (NCT01588119). 2018 , 262, 85-91		59
384	Fatal Adverse Event with Dabigatran in Elderly Patient with Reduced Kidney Function. 2018 , 123, 221-226		2
383	Rivaroxaban plasma levels in acute ischemic stroke and intracerebral hemorrhage. 2018 , 83, 451-459		29
382	International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants. <i>Thrombosis and Haemostasis</i> , 2018 , 118, 437-450	7	159
381	Kidney function monitoring and nonvitamin K oral anticoagulant dosage in atrial fibrillation. <i>European Journal of Clinical Investigation</i> , 2018 , 48, e12907	4.6	9
380	Atherothrombosis and Thromboembolism: Position Paper from the Second Maastricht Consensus Conference on Thrombosis. <i>Thrombosis and Haemostasis</i> , 2018 , 118, 229-250	7	32
379	Point of Care Testing (POCT) to assess drug concentration in patients treated with non-vitamin K antagonist oral anticoagulants (NOACs). <i>Thrombosis Research</i> , 2018 , 163, 100-104	8.2	7
378	Simulation for Predicting Effectiveness and Safety of New Cardiovascular Drugs in Routine Care Populations. <i>Clinical Pharmacology and Therapeutics</i> , 2018 , 104, 1008-1015	6.1	3
377	Risk of Recurrent Ischemic Stroke with Unintended Low-Dose Oral Anticoagulant Therapy and Optimal Timing of Review. 2018 , 27, 1546-1551		16
376	Implementation of smart technology to improve medication adherence in patients with cardiovascular disease: is it effective?. 2018 , 15, 119-126		22
375	The effect of oral dabigatran etexilate on bone density, strength, and microstructure in healthy mice. 2018 , 8, 9-17		8
374	Discrepancies between the use of MDRD-4 IDMS and CKD-EPI equations, instead of the Cockcroft-Gault equation, in the determination of the dosage of direct oral anticoagulants in patients with non-valvular atrial fibrillation. 2018 , 150, 85-91		
373	[Anticoagulation in geriatric patients with atrial fibrillation : With what and for whom no more?]. 2018 , 43, 214-221		2
372	Clinical implications of genetic variation in carboxylesterase drug metabolism. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018 , 14, 131-142	5.5	11

371	The anticoagulant effect of therapeutic levels of dabigatran in atrial fibrillation evaluated by thrombelastography (TEG), Hemoclot Thrombin Inhibitor (HTI) assay and Ecarin Clotting Time (ECT). 2018 , 78, 25-30		10
370	Non-Vitamin K-Dependent Oral Anticoagulants for Nonvalvular Atrial Fibrillation in Patients With CKD: Pragmatic Considerations for the Clinician. 2018 , 72, 717-727		10
369	Pharmacokinetics/Pharmacodynamics of Dabigatran 75 mg Twice Daily in Patients With Nonvalvular Atrial Fibrillation and Severely Impaired Renal Function. 2018 , 23, 399-406		7
368	The vexed question of whether or not to measure levels of direct oral anticoagulants before surgery or invasive procedures. 2018 , 13, 1029-1036		17
367	Anti-Xa activity in oral factor Xa inhibitor-treated patients with atrial fibrillation and a higher risk of bleeding: a pilot study. 2018 , 29, 369-373		9
366	Cardioembolic stroke: everything has changed. 2018 , 3, 76-83		21
365	Quantification of Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in Human Serum by UHPLC-MS/MS-Method Development, Validation, and Application. 2018 , 40, 369-376		13
364	The effect of dabigatran on thrombin generation and coagulation assays in rabbit and human plasma. <i>Thrombosis Research</i> , 2018 , 165, 38-43	8.2	8
363	Direct-acting oral anticoagulant drug level monitoring in clinical patient management. <i>Journal of Thrombosis and Thrombolysis</i> , 2018 , 45, 543-549	5.1	26
362	The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. 2018 , 39, 1330-1393		1094
361	Idarucizumab for dabigatran overdose in a child. 2018 , 180, 457-459		17
360	Non-vitamin K-dependent oral anticoagulants have a positive impact on ischaemic stroke severity in patients with atrial fibrillation. <i>Europace</i> , 2018 , 20, 569-574	3.9	24
359	Real-Life Peak and Trough Dabigatran Plasma Measurements over Time in Hospitalized Geriatric Patients with Atrial Fibrillation. 2018 , 22, 165-173		8
358	Comparison of Anti-Xa Activity in Patients Receiving Apixaban or Rivaroxaban. 2018 , 52, 251-256		8
357	Is there a role for pharmacokinetic/pharmacodynamic-guided dosing for novel oral anticoagulants?. 2018 , 199, 59-67		15
356	Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases. 2018 , 38, 6-18		21
355	Simultaneous quantification of direct oral anticoagulants currently used in anticoagulation therapy. 2018 , 148, 238-244		27
354	Dosing issues with non-vitamin K antagonist oral anticoagulants for the treatment of non-valvular atrial fibrillation: Why we should not underdose our patients. 2018 , 111, 85-94		22

353	Does type 2 diabetes affect the on-treatment levels of direct oral anticoagulants in patients with atrial fibrillation?. 2018 , 135, 172-177		7
352	Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians. <i>Journal of Thrombosis and Haemostasis</i> , 2018 , 16, 209-219	15.4	177
351	Cholestatic liver injury as a side-effect of dabigatran and the use of coagulation tests in dabigatran intoxication and after reversal by idarucizumab in bleeding and sepsis. 2018 , 78, 1-5		8
350	Ritonavir-Boosted Protease Inhibitors but Not Cobicistat Appear Safe in HIV-Positive Patients Ingesting Dabigatran. 2018 , 62,		6
349	Discrepancies between the use of MDRD-4 IDMS and CKD-EPI equations, instead of the Cockcroft-Gault equation, in the determination of the dosage of direct oral anticoagulants in patients with non-valvular atrial fibrillation. 2018 , 150, 85-91		8
348	Left ventricular mural thrombus despite treatment with dabigatran and clopidogrel. 2018 , 2018,		2
347	Laboratory measures of coagulation among trauma patients on NOAs: results of the AAST-MIT. 2018 , 3, e000231		9
346	Rivaroxaban plasma levels in patients admitted for bleeding events: insights from a prospective study. 2018 , 16, 28		25
345	NCCN Guidelines Insights: Cancer-Associated Venous Thromboembolic Disease, Version 2.2018. 2018 , 16, 1289-1303		105
344	Association of Oral Anticoagulants and Proton Pump Inhibitor Cotherapy With Hospitalization for Upper Gastrointestinal Tract Bleeding. <i>JAMA - Journal of the American Medical Association</i> , 2018 , 320, 2221-2230	27.4	80
343	Rapid determination of anticoagulating effects of dabigatran in whole blood with rotational thromboelastometry and a thrombin-based trigger. <i>Journal of Thrombosis and Haemostasis</i> , 2018 , 16, 2462-2470	15.4	10
342	A simple and fast HPLC-MS/MS method for simultaneous determination of direct oral anticoagulants apixaban, dabigatran, rivaroxaban in human plasma. 2018 , 1100-1101, 43-49		16
341	Basic coagulation tests as surrogates of dabigatran levels in a pre-operative setting: Analysis of five activated partial thromboplastin time reagents and thrombin time. <i>Thrombosis Research</i> , 2018 , 171, 62-67 ^{8,2}		3
340	Influence of Renal Function on the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Non-Vitamin K Antagonist Oral Anticoagulants. 2018 , 93, 1503-1519		7
339	Predictors of new oral anticoagulant drug initiation as opposed to warfarin in elderly adults: a retrospective observational study in Southern Italy. 2018 , 14, 1907-1914		3
338	Testing and monitoring direct oral anticoagulants. 2018 , 132, 2009-2015		39
337	Anticoagulation for Atrial Fibrillation in Patients with End- Stage Kidney Disease. 2018 ,		
336	Peak plasma concentration of direct oral anticoagulants in obese patients weighing over 120 kilograms: A retrospective study. 2018 , 2, 684-688		42

335	Drug interaction as a predictor of direct oral anticoagulant drug levels in atrial fibrillation patients. <i>Journal of Thrombosis and Thrombolysis</i> , 2018 , 46, 521-527	5.1	10
334	Elite athletes and anticoagulant therapy: an intermittent dosing strategy. 2018 , 2018, 412-417		9
333	Reducing risk of spinal haematoma from spinal and epidural pain procedures. 2018 , 18, 129-150		9
332	Dried-Blood-Spot Technique to Monitor Direct Oral Anticoagulants: Clinical Validation of a UPLC-MS/MS-Based Assay. 2018 , 90, 9395-9402		22
331	Gastrointestinal Bleeding With Edoxaban Versus Warfarin: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction). 2018 , 11, e003998		20
330	Guidelines for Gastroenterological Endoscopy in Patients Undergoing Antithrombotic Treatment: 2017 Appendix on Anticoagulants Including Direct Oral Anticoagulants. 2018 , 30, 433-440		72
329	Dabigatran Levels in Elderly Patients with Atrial Fibrillation: First Post-Marketing Experiences. 2018 , 35, 539-544		6
328	Proton Pump Inhibition in Patients Treated With Novel Antithrombotic Drugs: Should We Worry About Thrombosis?. 2018 , 72, 71-76		7
327	Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. Results from an international patient-level data meta-analysis. 2018 , 17, 1011-1021		80
326	Anticoagulation at the extremes of body weight: choices and dosing. 2018 , 11, 817-828		12
325	Comparison of rivaroxaban concentrations between Asians and Caucasians and their correlation with PT/INR. <i>Journal of Thrombosis and Thrombolysis</i> , 2018 , 46, 541-548	5.1	7
324	Establishing Therapeutic Equivalence of Complex Pharmaceuticals: The Case of Dabigatran. 2018 , 34, 1116-1119		4
323	A study on indices of apixaban anticoagulation: A single-center prospective study. 2018 , 137, 105-109		2
322	Phase 3, single-arm, multicenter study of dabigatran etexilate for secondary prevention of venous thromboembolism in children: Rationale and design. 2018 , 2, 580-590		3
321	Comparing the Efficacy and Safety of Direct Oral Anticoagulants With Warfarin in the Morbidly Obese Population With Atrial Fibrillation. 2019 , 53, 165-170		54
320	Fully automated thromboelastograph TEG 6s to measure anticoagulant effects of direct oral anticoagulants in healthy male volunteers. 2019 , 3, 391-396		20
319	Clinical Management of Pharmacokinetic Drug Interactions with Direct Oral Anticoagulants (DOACs). 2019 , 79, 1625-1634		12
318	Idarucizumab to revert the anticoagulant effect of dabigatran in traumatic acute subdural haematoma: a case report of first use in Latin America. 2019 , 3,		2

317	Direct-Acting Oral Anticoagulants in Critically Ill Patients. 2019 , 156, 604-618		4
316	Exposure Response Supports Therapeutic Drug Monitoring for Dabigatran Etexilate in Patients with Atrial Fibrillation. <i>TH Open</i> , 2019 , 3, e210-e215	2.7	1
315	Towards Personalized Antithrombotic Treatments: Focus on P2Y Inhibitors and Direct Oral Anticoagulants. 2019 , 58, 1517-1532		4
314	Direct oral anticoagulants and obesity: one size fits all?. 2019 , 6, e341-e342		
313	The effect of routine preoperative interruption of dabigatran therapy on coagulation parameters and dabigatran plasma levels in a mixed surgical population. 2019 , 47, 183-188		4
312	Anticoagulation in Concomitant Chronic Kidney Disease and Atrial Fibrillation: JACC Review Topic of the Week. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 2204-2215	15.1	45
311	Consideration of sex and gender in Cochrane reviews of interventions for preventing healthcare-associated infections: a methodology study. 2019 , 19, 169		9
310	Direct Oral Anticoagulant Plasma Levels for the Management of Acute Ischemic Stroke. 2019 , 48, 17-25		11
309	Unexpected excessive apixaban exposure: case report of a patient with polymorphisms of multiple apixaban elimination pathways. 2019 , 20, 53		7
308	Proton Pump Inhibitors and Dabigatran Therapy: Impact on Gastric Bleeding and Dabigatran Plasma Levels. 2019 , 45, 846-850		9
307	Antidotes for reversal of direct oral anticoagulants. 2019 , 204, 107405		6
306	Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 1760-1768	15.1	12
305	The continuous challenge of antithrombotic strategies in diabetes: focus on direct oral anticoagulants. 2019 , 56, 1247-1258		1
304	Management of Direct Oral Anticoagulants in Patients with Atrial Fibrillation Undergoing Cardioversion. 2019 , 55,		2
303	Long-Term Dabigatran Treatment Delays Alzheimer's Disease Pathogenesis in the TgCRND8 Mouse Model. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 1910-1923	15.1	38
302	Assessing Potential Drug-Drug Interactions Between Dabigatran Etexilate and a P-Glycoprotein Inhibitor in Renal Impairment Populations Using Physiologically Based Pharmacokinetic Modeling. 2019 , 8, 118-126		11
301	Horizontal vs. vertical dose reduction of direct oral anticoagulants in patients with non-valvular atrial fibrillation: definition and implications for practice. 2019 , 62, e11-e12		5
300	Progress in the monitoring of direct oral anticoagulant therapy. 2019 , 184, 912-924		21

299	Pharmacogenomics of Novel Direct Oral Anticoagulants: Newly Identified Genes and Genetic Variants. 2019 , 9,			37
298	Safety of direct oral anticoagulants in real-world clinical practice: translating the trials to everyday clinical management. 2019 , 18, 187-209			15
297	Impact of Total Antithrombotic Effect on Bleeding Complications in Patients Receiving Multiple Antithrombotic Agents. <i>Circulation Journal</i> , 2019 , 83, 1309-1316	2.9		2
296	The daily practice of direct oral anticoagulant use in patients with atrial fibrillation; an observational cohort study. 2019 , 14, e0217302			8
295	Apixaban Concentrations with Lower than Recommended Dosing in Older Adults with Atrial Fibrillation. 2019 , 67, 1902-1906			9
294	Oral anticoagulant monitoring: Are we on the right track?. 2019 , 41 Suppl 1, 40-48			4
293	A Comprehensive Whole-Body Physiologically Based Pharmacokinetic Model of Dabigatran Etextilate, Dabigatran and Dabigatran Glucuronide in Healthy Adults and Renally Impaired Patients. 2019 , 58, 1577-1593			8
292	Antithrombotic dose: Some observations from published clinical trials. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 2194-2197	3.8		1
291	The acceptability of a direct oral anticoagulant monitoring regimen among patients with atrial fibrillation: a pilot study. <i>International Journal of Clinical Pharmacy</i> , 2019 , 41, 682-686	2.3		1
290	Direct-Acting Oral Anticoagulants (DOACs) in Cirrhosis and Cirrhosis-Associated Portal Vein Thrombosis. 2019 , 39, 195-208			24
289	Oral anticoagulation therapy use in patients with atrial fibrillation after the introduction of non-vitamin K antagonist oral anticoagulants: findings from the French healthcare databases, 2011-2016. 2019 , 9, e026645			33
288	Genetic determinants of dabigatran safety (CES1 gene rs2244613 polymorphism) in the Russian population: multi-ethnic analysis. 2019 , 46, 2761-2769			3
287	Cerebral Ischemia in Patients on Direct Oral Anticoagulants. 2019 , 50, 873-879			27
286	Liquid chromatographic methods for the determination of direct oral anticoagulant drugs in biological samples: A critical review. 2019 , 1076, 18-31			14
285	Clinical experience of idarucizumab use in cases of cardiac tamponade under uninterrupted anticoagulation of dabigatran during catheter ablation of atrial fibrillation. <i>Journal of Thrombosis and Thrombolysis</i> , 2019 , 47, 487-494	5.1		10
284	Durability of cryoballoon left atrial appendage isolation: Acute and invasive remapping electrophysiological findings. 2019 , 42, 646-654			12
283	Use of dabigatran with antiretrovirals. 2019 , 20, 344-346			3
282	Rivaroxaban or Apixaban for Non-Valvular Atrial Fibrillation - Efficacy and Safety of Off-Label Under-Dosing According to Plasma Concentration. <i>Circulation Journal</i> , 2019 , 83, 991-999	2.9		14

281	The treatment pattern and adherence to direct oral anticoagulants in patients with atrial fibrillation aged over 65. 2019 , 14, e0214666		7
280	Pharmacokinetics and pharmacodynamics of oral anticoagulants used in atrial fibrillation. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019 , 15, 381-398	5.5	21
279	Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and 'Low Body Weight'. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 919-931	15.1	46
278	Low Body Weight and Prescribing 'DOACs in Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 932-934	15.1	1
277	Reduced Dose Direct Oral Anticoagulants in Older Adults with Atrial Fibrillation. 2019 , 8, 43-48		
276	Dabigatran levels in omeprazole versus pantoprazole-treated patients with atrial fibrillation: is there a difference?. <i>European Journal of Clinical Pharmacology</i> , 2019 , 75, 875-877	2.8	6
275	Life-threatening bleeding due to persistent dabigatran effect in a patient with sepsis despite idarucizumab therapy and haemodialysis. 2019 , 12,		4
274	Clinical use and laboratory testing of oral anticoagulation therapy: experience from Finland. 2019 , 4, 17-17		3
273	Reversing anticoagulation in the hemorrhaging patient. 2019 , 32, 206-212		1
272	Dabigatran for catastrophic antiphospholipid syndrome. 2019 , 30, 364-365		1
271	Use of direct oral anticoagulants in very elderly patients: a case report of apixaban in an ultracentenary patient. 2019 , 20, 403-405		3
270	Probable drug-drug interaction between dabigatran and quinidine resulting in thrombin time rebound despite multiple idarucizumab doses. 2019 , 30, 42-46		8
269	Effects of Oral Anticoagulants on Patients With Atrial Fibrillation Aged 90 Years and Older: Comparison Among Direct Oral Anticoagulant, Warfarin Anticoagulant, and Nonanticoagulation. 2019 , 74, 246-254		7
268	Clinical Pharmacokinetics and Pharmacodynamics of Direct Oral Anticoagulants in Patients with Renal Failure. 2019 , 44, 1-12		28
267	Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials. 2019 , 40, 1492-1500		31
266	Evaluation of combined idarucizumab and prothrombin complex concentrate treatment for bleeding related to dabigatran in a lethal porcine model of double trauma. 2019 , 59, 1376-1387		2
265	Direct oral anticoagulants in extremely obese patients: OK to use?. 2019 , 3, 152-155		18
264	The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V-Special Situations. <i>Thrombosis and Haemostasis</i> , 2019 , 119, 14-38	7	19

263	Roles of Coagulation Proteases and PARs (Protease-Activated Receptors) in Mouse Models of Inflammatory Diseases. 2019 , 39, 13-24		44
262	Dabigatran Toxicity in Acute Kidney Injury: Hemodialysis and Idarucizumab Required. 2019 , 4, 500-504		4
261	Serum Concentrations and Elimination Rates of Direct-Acting Oral Anticoagulants (DOACs) in Older Hip Fracture Patients Hospitalized for Surgery: A Pilot Study. 2019 , 36, 65-71		9
260	A level-headed approach to measuring direct oral anticoagulants: A 2-year retrospective analysis of DOAC levels from a tertiary UK centre. 2019 , 41, 200-207		5
259	Apixaban Levels in Octogenarian Patients with Non-valvular Atrial Fibrillation. 2019 , 36, 165-177		6
258	Idarucizumab dosing in patients with excessive dabigatran body burden. 2019 , 122, e20-e22		4
257	Adherence to dabigatran etexilate in atrial fibrillation patients intended to undergo electrical cardioversion. 2019 , 5, 91-99		4
256	Management strategies of the interaction between direct oral anticoagulant and drug-metabolizing enzyme inducers. <i>Journal of Thrombosis and Thrombolysis</i> , 2019 , 47, 590-595	5.1	9
255	Factors affecting serum concentration of dabigatran in Asian patients with non-valvular atrial fibrillation. 2019 , 118, 1154-1160		9
254	Anticoagulation in patients with Embolic Stroke of Unknown Source. 2019 , 14, 334-336		7
253	Association between activated partial thromboplastin time, age and bleeding events in NVAf patients receiving dabigatran. <i>European Journal of Clinical Pharmacology</i> , 2019 , 75, 321-328	2.8	2
252	How to proceed with long-term anticoagulation in patient after total gastrectomy and atrial fibrillation?. <i>European Journal of Clinical Pharmacology</i> , 2019 , 75, 285-286	2.8	4
251	Assessment of in vitro effects of direct thrombin inhibitors and activated factor X inhibitors through clot waveform analysis. 2019 , 72, 244-250		13
250	[Treatment with oral anticoagulants in older patients: Should warfarin still be prescribed?]. 2019 , 48, 154-164		2
249	Does proton pump inhibition change the on-treatment anti-Xa activity in xabans-treated patients with atrial fibrillation? A pilot study. <i>Journal of Thrombosis and Thrombolysis</i> , 2019 , 47, 140-145	5.1	6
248	The Impact of Proton Pump Inhibition on Dabigatran Levels in Patients With Atrial Fibrillation. 2019 , 26, e308-e313		23
247	Thrombin-induced platelet aggregation -effect of dabigatran using automated platelet aggregometry. 2020 , 31, 360-364		5
246	Creatinine clearance and inappropriate dose of rivaroxaban in Japanese patients with non-valvular atrial fibrillation. 2020 , 35, 110-117		4

245	Real-World Rivaroxaban and Apixaban Levels in Asian Patients With Atrial Fibrillation. <i>Clinical Pharmacology and Therapeutics</i> , 2020 , 107, 278-286	6.1	9
244	Patients with higher body mass index treated with direct / novel oral anticoagulants (DOAC / NOAC) for atrial fibrillation experience worse clinical outcomes. 2020 , 301, 90-95		16
243	Monitoring of low dabigatran concentrations: diagnostic performance at clinically relevant decision thresholds. <i>Journal of Thrombosis and Thrombolysis</i> , 2020 , 49, 457-467	5.1	3
242	A Pharmacokinetic Evaluation of Dabigatran Etxilate, Total Dabigatran, and Unconjugated Dabigatran Following the Administration of Dabigatran Etxilate Mesylate Capsules in Healthy Male and Female Subjects. 2020 , 70, 33-40		2
241	The Effect of Proton Pump Inhibitor Withdrawal on Dabigatran Etxilate Plasma Levels in Patients With Atrial Fibrillation: A Washout Study. 2020 , 75, 333-335		6
240	Practical considerations for the use of direct oral anticoagulants in oncology patients. 2020 , 26, 692-702		1
239	Anti-Xa Activity in Elderly Xabans-Treated Patients With Atrial Fibrillation. 2020 , 27, e507-e509		2
238	Use of Direct Oral Anticoagulants in Morbidly Obese Patients. 2020 , 40, 72-83		19
237	What are the Characteristics of Patients Experiencing Adverse Drug Reactions to Oral Anticoagulants and How Can Such Reactions be Prevented?. 2020 , 15, 38-44		3
236	Routine Therapeutic Drug Monitoring of Dabigatran: Experience at a Tertiary Center. 2020 , 42, 468-472		2
235	Non-vitamin K antagonist oral anticoagulants in very elderly east Asians with atrial fibrillation: A nationwide population-based study. 2020 , 229, 81-91		5
234	The relationship between DOAC levels and clinical outcomes: The measures tell the tale. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 3163-3168	15.4	6
233	Apixaban and rivaroxaban anti-Xa level utilization and associated bleeding events within an academic health system. <i>Thrombosis Research</i> , 2020 , 196, 276-282	8.2	8
232	Therapeutic Drug Monitoring of Direct Oral Anticoagulants May Increase Their Benefit-Risk Ratio. 2020 , 76, 472-477		8
231	[Direct oral anticoagulants: In which indications? Which one to prescribe? For or against their use in frail patients and in atypical cases? Which monitoring and management haemorrhage complications?]. 2020 , 41, 598-606		0
230	The CES1 Gene rs2244613 Minor Allele Impact on the Safety Profile of Dabigatran Etxilate: Meta-Analysis. <i>Rational Pharmacotherapy in Cardiology</i> , 2020 , 16, 699-705	0.5	
229	Diagnostic performance of coagulation indices for direct oral anticoagulant concentration. <i>Thrombosis Research</i> , 2020 , 195, 171-179	8.2	2
228	Body weight is negatively associated with direct oral anticoagulant trough concentrations in dabigatran and apixaban users. 2020 , 191, 941-944		2

227	The use and adherence of oral anticoagulants in Primary Health Care in Catalunya, Spain: A real-world data cohort study. 2020 , 52, 529-538			3
226	Anti-FXa-IIa activity test in Asian and its potential role for drug adherence evaluation in patients with direct oral anticoagulants: a nationwide multi-center synchronization study. 2020 , 10, 1293-1302			0
225	Stroke Prevention in Older Adults: Recent Advances. 2020 , 51, 3770-3777			8
224	Closure Device-Related Thrombosis After Anticoagulation With Dabigatran in Patients Undergoing Percutaneous Left Atrial Appendage Closure: Case Reports and Literature Review. 2020 , 11, 563920			4
223	Pulmonary Embolism. 2020 ,			
222	Flow Cytometric Assessment of Endothelial and Platelet Microparticles in Patients With Atrial Fibrillation Treated With Dabigatran. 2020 , 26, 1076029620972467			3
221	Prescribing Pattern of Oral Anticoagulants in Patients With Obesity. 2020 , 897190020969276			1
220	Direct-acting oral anticoagulant use at extremes of body weight: Literature review and recommendations. 2020 , 77, 865-876			7
219	A single center retrospective cohort study evaluating use of direct oral anticoagulants (DOACs) in morbidly obese veteran population. <i>Thrombosis Research</i> , 2020 , 192, 124-130	8.2		12
218	Non-Vitamin K Antagonist Oral Anticoagulants and the Gastrointestinal Bleeding Risk in Real-World Studies. 2020 , 9,			5
217	Non-Vitamin K Antagonist Oral Anticoagulant for Atrial Fibrillation in Obese Patients. 2020 , 127, 176-183			8
216	Clinical implications of assessment of apixaban levels in elderly atrial fibrillation patients: J-ELD AF registry sub-cohort analysis. <i>European Journal of Clinical Pharmacology</i> , 2020 , 76, 1111-1124	2.8		8
215	Does One Dose Really Fit All? On the Monitoring of Direct Oral Anticoagulants: A Review of the Literature. 2020 , 40, 184-200			9
214	Effect of Sex, Use of Pantoprazole and Polymorphisms in SLC22A1, ABCB1, CES1, CYP3A5 and CYP2D6 on the Pharmacokinetics and Safety of Dabigatran. 2020 , 37, 3537-3550			4
213	Select Drug-Drug Interactions With Direct Oral Anticoagulants: JACC Review Topic of the Week. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 1341-1350	15.1		40
212	Ischemic stroke and dose adjustment of oral Factor Xa inhibitors in patients with atrial fibrillation. 2020 , 267, 2007-2012			6
211	Monitoring the roles of prothrombin activation fragment 1 and 2 (F1 + 2) in patients with atrial fibrillation receiving rivaroxaban and apixaban. <i>Journal of Thrombosis and Thrombolysis</i> , 2020 , 50, 371-379	5.1		0
210	Drug-Drug Interactions with Direct Oral Anticoagulants. 2020 , 59, 967-980			34

209	Switching from vitamin K antagonists to direct oral anticoagulants: Treatment satisfaction and patient concerns. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 1390-1397	15.4	4
208	Disruption of the kringle 1 domain of prothrombin leads to late onset mortality in zebrafish. <i>Scientific Reports</i> , 2020 , 10, 4049	4.9	2
207	May Increase the Risk of Death Among Patients with an Acute Coronary Syndrome and Non-Valvular Atrial Fibrillation Who Receive Clopidogrel and Rivaroxaban. 2020 , 13, 29-37		4
206	Novel antithrombotic effects of dabigatran in patients with non-valvular atrial fibrillation. <i>Thrombosis Research</i> , 2020 , 189, 1-4	8.2	2
205	Whole Blood Point-of-Care Testing for Incomplete Reversal With Idarucizumab in Supratherapeutic Dabigatran. 2020 , 130, 535-541		6
204	Concentrations of dabigatran administered after acute ischemic stroke. 2020 , 411, 116704		2
203	Effective Removal of Dabigatran by Idarucizumab or Hemodialysis: A Physiologically Based Pharmacokinetic Modeling Analysis. 2020 , 59, 809-825		2
202	Incomplete responses to the recommended dose of idarucizumab: a systematic review and pharmacokinetic analysis. 2020 , 1-12		1
201	Rivaroxaban Precision Dosing Strategy for Real-World Atrial Fibrillation Patients. 2020 , 13, 777-784		6
200	Interindividual Variability of Apixaban Plasma Concentrations: Influence of Clinical and Genetic Factors in a Real-Life Cohort of Atrial Fibrillation Patients. 2020 , 11,		6
199	Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation. <i>Journal of Thrombosis and Thrombolysis</i> , 2020 , 50, 20-29	5.1	7
198	Should we monitor the direct oral anticoagulants?. <i>Journal of Thrombosis and Thrombolysis</i> , 2020 , 50, 30-32	5.1	4
197	Direct oral anticoagulant plasma levels' striking increase in severe COVID-19 respiratory syndrome patients treated with antiviral agents: The Cremona experience. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 1320-1323	15.4	103
196	How I treat obese patients with oral anticoagulants. 2020 , 135, 904-911		10
195	Use of direct-acting oral anticoagulants in solid organ transplantation: A systematic review. 2021 , 41, 28-43		4
194	Position paper on the safety/efficacy profile of Direct Oral Anticoagulants in patients with Chronic Kidney Disease: Consensus document of Societ� Italiana di Nefrologia (SIN), Federazione Centri per la diagnosi della trombosi e la Sorveglianza delle terapie Antitrombotiche (FCSA) and Societ�		3
193	Quantitative Benefit-Risk Assessment of P-gp-Mediated Drug-Drug Interactions of Dabigatran Coadministered With Pharmacokinetic Enhancers in Patients With Renal Impairment. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 109, 193-200	6.1	2
192	Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 511-525	15.1	3

191	The impact of ABCB1 and CES1 polymorphisms on dabigatran pharmacokinetics and pharmacodynamics in patients with atrial fibrillation. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 2247-2255	3.8	6
190	Evaluation of Extended-Interval Dabigatran Dosing in Older Patients With Non-Valvular Atrial Fibrillation. 2021 , 26, 359-364		1
189	Monitoring DOACs with a Novel Dielectric Microsensor: A Clinical Study. <i>Thrombosis and Haemostasis</i> , 2021 , 121, 58-69	7	5
188	[Who should supervise anticoagulant treatment and how?]. 2021 , 38 Suppl 1, e113-e119		2
187	Pharmacogenetics of Direct Oral Anticoagulants: A Systematic Review. 2021 , 11,		19
186	A review of indications and comorbidities in which warfarin may be the preferred oral anticoagulant. 2021 , 46, 560-570		2
185	Healthcare resource utilization and costs of rivaroxaban versus warfarin among non-valvular atrial fibrillation (NVAf) patients with obesity in a US population. 2021 , 24, 550-562		2
184	Empfehlungen zur prähospitalen Behandlung des akuten Koronarsyndroms bei Patienten unter Dauertherapie mit neuen oralen Antikoaganzien (NOAKs). 2021 , 15, 32-37		1
183	Non-Vitamin K Antagonist Oral Anticoagulants (NOACs) Versus Warfarin in Patients with Atrial Fibrillation and (Morbid) Obesity or Low Body Weight: a Systematic Review and Meta-Analysis. 2021 , 1		6
182	Dabigatran Reversal With Idarucizumab in 2 Patients With Portal Vein Thrombosis Undergoing Orthotopic Liver Transplantation. 2021 , 25, 200-207		0
181	The "Obesity Paradox" and the Use of NOAC. 2021 , 149-178		1
180	Comparative effectiveness and safety of high-dose rivaroxaban and apixaban for atrial fibrillation: A propensity score-matched cohort study. 2021 , 41, 379-393		0
179	Oral Anticoagulant Adequacy in Non-Valvular Atrial Fibrillation in Primary Care: A Cross-Sectional Study Using Real-World Data (Fantas-TIC Study). 2021 , 18,		1
178	Direct Oral Anticoagulants Plasma Levels Measurement: Clinical Usefulness from Trials and Real-World Data. 2021 , 47, 150-160		3
177	Direct Oral Anticoagulants in Atrial Fibrillation: Practical Considerations and Remaining Issues. 2021 , 41, 35-41		0
176	Analysis of the Introduction in Clinical Practice of New Oral Anticoagulants in Local Health Agency BT: Translation of the Clinical Trial Data to a Local Health Care Area. <i>Pharmaceutics</i> , 2021 , 13,	6.4	1
175	Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial. 2021 , 143, 673-684		2
174	2021 Update of the International Council for Standardization in Haematology Recommendations for Laboratory Measurement of Direct Oral Anticoagulants. <i>Thrombosis and Haemostasis</i> , 2021 , 121, 1008-1020 ²¹	7	

173	The relationship between DOAC levels and clinical outcomes: The measures tell the tale-Response from original authors Lijfering et al. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 1136-1138	15.4	0
172	Stroke due to Left Atrial Appendage Thrombus after Pulmonary Vein Isolation despite Novel Oral Anticoagulant: A Case Report. 2021 , 13, 225-232		0
171	Laboratory Monitoring of Direct Oral Anticoagulants (DOACs). 2021 , 9,		7
170	Difficult reversal of dabigatran with idarucizumab in a multiple-trauma patient: A question of dose?. 2021 , 32, 100422		0
169	How lower doses of direct oral anticoagulants are interpreted in clinical practice: a national survey of the Italian Atherosclerosis, Thrombosis and Vascular Biology (ATVB) Study Group. 2021 , 22, 924-928		0
168	The pleiotropic effects of antithrombotic drugs in the metabolic-cardiovascular-neurodegenerative disease continuum: impact beyond reduced clotting. 2021 , 135, 1015-1051		1
167	2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. <i>Europace</i> , 2021 , 23, 1612-1676	3.9	99
166	Diagnosis and Management of Pediatric Venous Thromboembolism: New Therapies on the Horizon. 2021 , 37, 273-279		
165	Direct oral anticoagulant blood level monitoring in daily practice. 2021 , 3, 100049		1
164	Treatment of venous thromboembolism in cancer patients: The dark side of the moon. 2021 , 96, 102190		3
163	Measurement of Dabigatran Concentration Using Finger Prick Dried Blood Spot Sample Collection. 2021 , 12, 679431		
162	A simple and sensitive HILIC-based UHPLC-MS/MS method for quantifying of rivaroxaban in dried blood spots: Application in comparison with the plasma sample method. 2021 , 198, 114023		1
161	Body Mass Index Influence on the Clinical Outcomes for Nonvalvular Atrial Fibrillation Patients Admitted to a Hospital Treated with Direct Oral Anticoagulants: A Retrospective Cohort Study. 2021 , 15, 1931-1943		0
160	Stroke Prevention: Little-Known and Neglected Aspects. 2021 , 50, 622-635		2
159	Oral drug dosing following bariatric surgery: General concepts and specific dosing advice. <i>British Journal of Clinical Pharmacology</i> , 2021 ,	3.8	3
158	Alternatives for Vitamin K Antagonists as Thromboprophylaxis for Mechanical Heart Valves and Mechanical Circulatory Support Devices: A Systematic Review. 2021 , 47, 724-734		1
157	Pharmacogenetics of Bleeding and Thromboembolic Events in Direct Oral Anticoagulant Users. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 110, 768-776	6.1	6
156	Direct Oral Anticoagulants Versus Warfarin in Morbidly Obese Patients With Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-analysis. 2021 , 28, e531-e539		4

155	Plasma levels do not predict thrombin generation in patients taking direct oral anticoagulants. 2021 , 43, 1539-1548		1
154	The Importance of Appropriate Dosing of Nonvitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation. <i>TH Open</i> , 2021 , 5, e353-e362	2.7	2
153	Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 1874-1882	15.4	20
152	Perpetrator Characteristics of Azole Antifungal Drugs on Three Oral Factor Xa Inhibitors Administered as a Microdosed Cocktail. 2021 , 1		1
151	Direct Oral Anticoagulants Plasma Levels in Patients with Atrial Fibrillation at the Time of Bleeding: A Pilot Prospective Study. 2021 , 78, e122-e127		3
150	Modulating the Intensity of Oral Anticoagulation Therapy with Direct Oral Anticoagulants: Feasible or Not?. 2021 , 1		1
149	MicroRNAs as novel biomarkers for rivaroxaban therapeutic drug monitoring. <i>Drug Metabolism and Personalized Therapy</i> , 2021 ,	2	
148	Oral Anticoagulant Use in Patients with Morbid Obesity: A Systematic Review and Meta-Analysis. <i>Thrombosis and Haemostasis</i> , 2021 ,	7	1
147	Pharmacokinetics of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Extreme Obesity. 2021 , 43, e255-e263		2
146	Medications that interact with direct-acting oral anticoagulant exposure. 2021 , 29, 417-418		
145	Oral Anticoagulant Use in Morbid Obesity and Post Bariatric Surgery: A Review. 2021 ,		1
144	Drug-Drug Interactions with Direct Oral Anticoagulants: Practical Recommendations for Clinicians. 2021 , 134, 939-942		3
143	Estimated Thresholds of Minimum Necessary Adherence for Effective Treatment with Direct Oral Anticoagulants - A Retrospective Cohort Study in Health Insurance Claims Data. 2021 , 15, 2209-2220		2
142	Comparative Effectiveness and Safety of Direct Oral Anticoagulants in Obese Patients with Atrial Fibrillation. 2021 , 35, 261-272		9
141	Antithrombotika und Antihorrhagika. 2018 , 401-421		2
140	Antithrombotika und Antihorrhagika. 2019 , 531-555		3
139	Gestion pharmaceutique des anticoagulants oraux directs. 2019 , 2019, 2-6		1
138	Different Coagulation Indicators in Predicting Clinical Outcomes for Patients With Direct Oral Anticoagulants: A Systematic Review and Meta-analysis. 2020 , 42, 2066-2081.e9		2

137	The effect of bariatric surgery on direct-acting oral anticoagulant drug levels. <i>Thrombosis Research</i> , 2018 , 163, 190-195	8.2	36
136	Haemostaseological complication management in caval and iliac venous stenting. 2018 , 47, 243-246		1
135	Assessing and Reversing the Effect of Direct Oral Anticoagulants on Coagulation. 2020 , 133, 223-232		1
134	Plasma lipids affect dabigatran etexilate anticoagulation in rats with unbalanced diabetes mellitus. 2018 , 10, 240-248		3
133	Dabigatran reversal with idarucizumab prior to lung transplantation. 2021 , 35, e14142		2
132	Direct Oral Anticoagulants in Obesity: An Updated Literature Review. 2020 , 54, 1144-1158		10
131	Monitoring and reversal of direct oral anticoagulants. 2015 , 2015, 117-124		9
130	Major bleeding events in octagenarians associated with drug interactions between dabigatran and P-gp inhibitors. 2019 , 16, 806-811		5
129	Anticoagulation in frail older people. 2019 , 16, 844-846		4
128	Management of Atrial Fibrillation in COVID-19 Pandemic. <i>Circulation Journal</i> , 2020 , 84, 1679-1685	2.9	9
127	Risk of Ischemic Stroke, Hemorrhagic Stroke, Bleeding, and Death in Patients Switching from Vitamin K Antagonist to Dabigatran after an Ablation. 2016 , 11, e0161768		2
126	Perioperative management of antithrombotic and antiplatelet therapy. 2015 , 42, 239-42		6
125	Analysis of bioMARKer Distribution and Individual Reproducibility Under Rivaroxaban Treatment in Japanese Patients with Non-Valvular Atrial Fibrillation (R-MARK Study, CVI ARO2). 2020 , 61, 695-704		1
124	Clinical pharmacology technologies for personalization of cardiovascular diseases drug treatment: focus on direct oral anticoagulants. 2019 , 74, 299-306		1
123	Long-term prescribing of new oral anticoagulants. 2016 , 39, 200-204		7
122	Position Paper on laboratory testing for patients on direct oral anticoagulants. A Consensus Document from the Siset, FCSA, SIBioC and SIPMeL. 2018 , 16, 462-470		35
121	Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis. 2017 , 21, 1-386		90
120	2018 KHRS Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Korean Patients with Atrial Fibrillation: How to Initiate and Organize the Follow-up. 2019 , 94, 17-39		1

119	Use of novel oral anticoagulant agents in atrial fibrillation: current evidence and future perspective. 2014 , 4, 314-23	9
118	[Safer treatment with serum concentration monitoring of the new anticoagulants?]. 2016 , 136, 1556-1560	3
117	Dabigatran plasma concentration indicated the risk of patients with non-valvular atrial fibrillation. 2021 , 1	0
116	Assessment of exposure to direct oral anticoagulants in elderly hospitalised patients. 2021 , 195, 790-801	0
115	[Can new anticoagulants be more risky than previously assumed?]. 2014 , 134, 817	1
114	The concept of dose modification for lowering the risk of bleeding with non-vitamin k oral anticoagulant drugs: How to choose the right dose?. 2014 , 33, 216-219	
113	?????????????. 2014 , 33, 419-420	
112	Neue orale Antikoagulanzen in der perioperativen Medizin. 2015 , 107-122	
111	Risk Factors for the Prolongation of Activated Partial Thromboplastin Time Associated with Dabigatran Therapy in Patients with Non-Valvular Atrial Fibrillation. 2015 , 46, 179-184	
110	Anticoagulation Drugs: Indications, Therapeutic Monitoring, and Antidotes. 2016 , 503-517	
109	Atrial Fibrillation on Vitamin K Antagonist Oral Anticoagulant Undergoing Primary Percutaneous Coronary Intervention for ST-Elevation Acute Myocardial Infarction. 2017 , 95-120	
108	Distinguishing between Individual Direct Oral Anticoagulants on the Basis of their Specific Characteristics. 2018 , 14, 113-120	
107	A Low Rivaroxaban Plasma Level May Indicate Anticoagulation Undertreatment. 2018 , 5, 000937	
106	Consenso sulla diagnostica di laboratorio per i pazienti in trattamento con farmaci anticoagulanti ad azione diretta. Sottoscritto dalla Società Italiana per lo Studio dell'Emostasi e della Trombosi (SISSET), dalla Federazione Centri per la diagnosi della trombosi e la Sorveglianza delle terapie Antitrombotiche (FCSA), dalla Società Italiana di Biochimica Clinica e Biologia Molecolare Clinica (SIBioC) e dalla Società Italiana di Patologia Clinica e Medicina di Laboratorio (SIPMeL). 2019 , 15, Cardioembolic stroke, the basis of diagnosis and prevention. 2019 , 55-58	0
104	[Personalized approach for direct oral anticoagulant prescription: from theory to practice]. 2019 , 91, 111-120	3
103	Manejo das Hemorragias Relacionadas aos Anticoagulantes Orais de Ação Direta. 2019 , 32, 89-96	
102	Management of Hemorrhage Related to Direct Action Oral Anticoagulant Medication. 2019 , 32, 89-96	

- 101 Reversal of Oral Anticoagulants in the Elderly. **2020**, 67-75
- 100 Treatment for Pulmonary Embolism: Anticoagulation Selection and Duration. **2020**, 57-83
- 99 Antithrombotika und Antihorrhagika. **2020**, 395-420
- 98 Idarucizumab for dabigatran reversal in the patient with subarachnoid hemorrhage. **2020**, 27, 24-27
- 97 Prolonged Coagulopathy With Dabigatran Despite Multiple Doses of Idarucizumab: A Case of Incomplete Reversal. **2020**, 0
- 96 Advances and Application of a Novel Oral Anticoagulant in Specific Populations: Dabigatran Etxilate. **2020**, 21, 106-111
- 95 Remedial dosing recommendation for delayed or missed rivaroxaban doses for patients with non-valvular atrial fibrillation based on Monte Carlo simulation.
- 94 Recent advances in preventing recurrent stroke. **2020**, 9,
- 93 Risk factors and one-year mortality in patients with direct oral anticoagulant-associated gastrointestinal bleeding. *Thrombosis Research*, **2021**, 208, 138-144 8.2 0
- 92 Impact of Renal Function on Effectiveness and Safety Associated With Low Dose Dabigatran in Non-valve Atrial Fibrillation Patients After Catheter Ablation. *Frontiers in Cardiovascular Medicine*, **2021**, 8, 762872 5.4
- 91 Inter- and intra-individual concentrations of direct oral anticoagulants: The KIDOAC study. *Journal of Thrombosis and Haemostasis*, **2021**, 20, 92 15.4 3
- 90 Anticoagulation Treatment and Outcomes of Venous Thromboembolism by Weight and Body Mass Index: Insights From the Veterans Health Administration. **2021**, 14, e008005 0
- 89 DOAC drug levels: Does "knowing" lead to safer care?. *Thrombosis Research*, **2021**, 208, 127-128 8.2
- 88 Dabigatran trough concentrations in very elderly patients. **2021**, 28, 231-233 1
- 87 Dosage of Anticoagulants in Obesity: Recommendations Based on a Systematic Review. **2020**, 46, 932-969 3
- 86 Advances in the management of atrial fibrillation with a special focus on non-pharmacological approaches to prevent thromboembolism: a review of current recommendations. **2020**, 68, 1317-1333
- 85 Does the FDA Owe Us an Explanation?. **2015**, 8, 1361
- 84 Testing direct oral anticoagulants: embedding in structured long-term care. **2018**, 16, 410-412 1

83	Position paper on the safety/efficacy profile of direct oral anticoagulants in patients with chronic kidney disease. Consensus document from the SIN, FCSA and Siset. 2020 , 18, 478-485		
82	Adherence with direct oral anticoagulants in patients with atrial fibrillation: Trends, risk factors, and outcomes.. <i>Journal of Arrhythmia</i> , 2022 , 38, 67-76	1.5	
81	Emergency cardiac surgery in patients on oral anticoagulants and antiplatelet medications. 2022 , 37, 214-222		
80	Retrospective analysis of the effectiveness of a reduced dose of idarucizumab in dabigatran reversal. <i>Thrombosis and Haemostasis</i> , 2021 ,	7	0
79	Antithrombotika und Antihorrhagika. 2021 , 299-326		0
78	Gender Differences and Evidence-Based Medicine: Navigating the Wide Knowledge Gap. 2020 ,		
77	Serum or Plasma for Quantification of Direct Oral Anticoagulants?. 2022 ,		1
76	Low Exposure to Direct Oral Anticoagulants Is Associated with Ischemic Stroke and Its Severity.. <i>Journal of Stroke</i> , 2022 , 24, 88-97	5.6	1
75	References. 2022 , 461-481		
74	Case series of massive direct oral anticoagulant ingestion - treatment and pharmacokinetics data.. <i>European Journal of Clinical Investigation</i> , 2022 , e13746	4.6	0
73	Plasma levels of direct oral anticoagulants in atrial fibrillation patients at the time of embolic stroke: a pilot prospective multicenter study.. <i>European Journal of Clinical Pharmacology</i> , 2022 , 78, 557	2.8	2
72	Can a Single Measurement of Apixaban Levels Identify Patients at Risk of Overexposure? A Prospective Cohort Study.. <i>TH Open</i> , 2022 , 6, e10-e17	2.7	2
71	Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: A Position Paper from the ESC Working Group on Thrombosis, in collaboration with the European Heart Rhythm Association, the Association for Acute CardioVascular Care and the Asia-Pacific Heart Rhythm Society.. <i>Europace</i> , 2022 ,	3.9	1
70	Major Bleeding Risk in Patients With Non-valvular Atrial Fibrillation Concurrently Taking Direct Oral Anticoagulants and Antidepressants.. <i>Frontiers in Aging Neuroscience</i> , 2022 , 14, 791285	5.3	2
69	Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation.. <i>JAMA - Journal of the American Medical Association</i> , 2021 , 326, 2395-2404	27.4	14
68	The value and limitations of new oral anticoagulant plasma level assessments.. <i>European Heart Journal Supplements</i> , 2022 , 24, A32-A41	1.5	0
67	Absorption of Direct Oral Anticoagulants in Cancer Patients after Gastrectomy.. <i>Pharmaceutics</i> , 2022 , 14,	6.4	1
66	JCS/JHRS 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias. <i>Journal of Arrhythmia</i> ,	1.5	

65	Monitoring of Direct Oral Anticoagulants Plasma Levels for Secondary Stroke Prevention.. <i>Journal of Thrombosis and Haemostasis</i> , 2022 ,	15.4	1
64	JCS/JHRS 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias.. <i>Circulation Journal</i> , 2022 , CJ-20-1212	12	6
63	MicroRNAs as novel biomarkers for rivaroxaban therapeutic drug monitoring.. <i>Drug Metabolism and Personalized Therapy</i> , 2021 , 37, 41-46	2	0
62	Impact of different renal function equations on direct oral anticoagulant concentrations.. <i>Scientific Reports</i> , 2021 , 11, 23833	4.9	0
61	Evaluating pharmacokinetic drug-drug interactions of direct oral anticoagulants in patients with renal dysfunction.. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2022 , 1-14	5.5	
60	Management of Patients with Embolic Stroke of Unknown Source: Interpreting the Evidence in the Light of Clinical Judgement.. <i>Current Neurology and Neuroscience Reports</i> , 2022 , 1	6.6	0
59	SLC4A4, FRAS1, and SULT1A1 Genetic Variations Associated With Dabigatran Metabolism in a Healthy Chinese Population. <i>Frontiers in Genetics</i> , 2022 , 13,	4.5	1
58	Anticoagulants: dose control methods and inhibitors. <i>Obstetrics, Gynecology and Reproduction</i> , 2022 , 16, 158-175	0.5	0
57	Drug-drug interactions: Implications for anticoagulation, with focus in patients with cancer. <i>Thrombosis Research</i> , 2022 , 213, S66-S71	8.2	1
56	A systematic review and meta-analysis of dabigatran peak and trough concentration in adults. <i>British Journal of Clinical Pharmacology</i> ,	3.8	
55	Evaluation of safety and efficacy outcomes of direct oral anticoagulants versus warfarin in normal and extreme body weights for the treatment of atrial fibrillation or venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> ,	5.1	0
54	Practical recommendations to combine small-molecule inhibitors and direct oral anticoagulants in patients with nonsmall cell lung cancer. <i>European Respiratory Review</i> , 2022 , 31, 220004	9.8	0
53	Anticoagulants. 2022 , 223-231		
52	Direct Oral Anticoagulants vs. Warfarin in Hemodialysis Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis. <i>Frontiers in Cardiovascular Medicine</i> , 9,	5.4	0
51	Modern possibilities and prospects in evaluating the anticoagulant effect of direct oral anticoagulants. <i>Atherothrombosis</i> , 2022 , 12, 20-28	0.3	
50	Clinically Significant Drug Interactions for Direct Oral Anticoagulants: State of the Art. <i>Rational Pharmacotherapy in Cardiology</i> , 2022 , 18, 332-341	0.5	
49	Leveraging a previously published population pharmacokinetic model to predict rivaroxaban exposure in real-world patients. <i>Journal of Clinical Pharmacology</i> ,	2.9	
48	A retrospective cohort study of the effectiveness and safety of dabigatran versus rivaroxaban in overweight patients with nonvalvular atrial fibrillation. <i>International Journal of Clinical Pharmacy</i> ,	2.3	

47	Personalizing Direct Oral Anticoagulant Therapy for a Diverse Population: Role of Race, Kidney Function, Drug Interactions and Pharmacogenetics. <i>Clinical Pharmacology and Therapeutics</i> ,	6.1	1
46	Assessment and Mitigation of Bleeding Risk in Atrial Fibrillation and Venous Thromboembolism: Executive Summary of a European and Asia-Pacific Expert Consensus Paper. <i>Thrombosis and Haemostasis</i> ,	7	3
45	Hemoclot Thrombin Inhibitor Assay and Expected Peak-Trough Levels of Dabigatran: A Multicenter Study. 9,		
44	Do Apixaban Plasma Levels Relate to Bleeding? The Clinical Outcomes and Predictive Factors for Bleeding in Patients with Non-Valvular Atrial Fibrillation. 2022 , 10, 2001		o
43	Comparing Safety and Efficacy of Direct Oral Anticoagulants Versus Warfarin in Extreme Obesity. 089719002211168		
42	Adherence, persistence and switching rates of apixaban, dabigatran and rivaroxaban in non-valvular atrial fibrillation: a multicentre real-life analysis at 3 years. ejhpharm-2022-003338		
41	An Auxiliary Scoring Model for Patients with Acute Pulmonary Embolism Complicated with Atrial Fibrillation Was Established Based on Random Forests. 2022 , 2022, 1-8		
40	Safety of non-vitamin K antagonist oral anticoagulants: concerns in patients with atrial fibrillation and glomerular hyperfiltration?.		o
39	Pharmacogenomics Informs Cardiovascular Pharmacotherapy. 2022 , 201-240		o
38	Rapid Detection of Apixaban by a ROTEM-Based Approach and Reversibility with Andexanet Alfa or DOAC-Stop. 2022 , 06, e238-e247		o
37	Dilemmas in the Choice of Adequate Therapeutic Treatment in Patients with Acute Pulmonary Embolism—from Modern Recommendations to Clinical Application. 2022 , 15, 1146		o
36	Pharmakologische Eigenschaften mit Praxisrelevanz. 2022 , 33, 50-60		o
35	The non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with high-normal renal function—a systematic review. 2022 , 107123		o
34	Een cardiocerebraal stollingsdilemma bij een oudere patiënte.		o
33	Tailored Direct Oral Anticoagulation in Patients with Atrial Fibrillation: The Future of Oral Anticoagulation?. 2022 , 11, 6369		o
32	Effect of Genotype on the Pharmacokinetics and Bleeding Events of Direct Oral Anticoagulants: A Systematic Review and Meta-analysis.		o
31	Population pharmacokinetic analysis for dabigatran etexilate in Chinese patients with non-valvular atrial fibrillation. 9,		o
30	Carboxylesterase-2 plays a critical role in dabigatran etexilate active metabolite formation. 2022 , 100479		o

- 29 Gastrointestinal Bleeding Due to NOACs Use: Exploring the Molecular Mechanisms. **2022**, 23, 13955 ○
- 28 Safety and efficacy of direct oral anticoagulants in geriatric patients with non-valvular atrial fibrillation: A single-center retrospective study. **2022**, ○
- 27 Impact of dabigatran dose on drug levels in asian patients with atrial fibrillation or venous thromboembolism: evidence from pharmacological to clinical outcomes. ○
- 26 Acute, periprocedural and longterm antithrombotic therapy in older adults. ○
- 25 Prothrombin Time-International Normalized Ratio Predicts the Outcome of Atrial Fibrillation Patients Taking Rivaroxaban. **2022**, 10, 3210 ○
- 24 Genetic variations in relation to bleeding and pharmacodynamics of dabigatran in Chinese patients with nonvalvular atrial fibrillation: A nationwide multicentre prospective cohort study. **2022**, 12, ○
- 23 Minimizing drug-drug interactions between dabigatran and levetiracetam through clinical management: a case report. ○
- 22 Physiologically-Based Pharmacokinetic Modeling to Predict Drug-drug Interactions of Dabigatran Etexilate and Rivaroxaban in the Chinese Older Adults. **2023**, 106376 ○
- 21 Supratherapeutic dabigatran: a cause of life-threatening haemorrhage*. **2023**, 11, ○
- 20 Warfarin Time in Therapeutic INR Range and Direct Oral Anticoagulant Adherence for Venous Thromboembolism Across the Spectrum of Weight and Body Mass Index: Findings from Veterans Health Administration. **2023**, 29, 107602962311524 ○
- 19 Pharmacokinetics and Dosing Regimens of Direct Oral Anticoagulants in Morbidly Obese Patients: An Updated Literature Review. **2023**, 29, 107602962311536 ○
- 18 Safety and Efficacy Re-Evaluation of Edoxaban and Rivaroxaban Dosing With Plasma Concentration Monitoring in Non-Valvular Atrial Fibrillation: With Observations of On-Label and Off-Label Dosing. **2023**, 5, 80-89 ○
- 17 The role of anticoagulation clinics needs to be reassessed to include follow up of patients on direct oral anticoagulants. **2023**, 225, 11-15 ○
- 16 DOACs plasma levels in relation to clinical outcome. How far have we come?. **2023**, 225, 16-21 ○
- 15 Challenges in Cardiovascular Evaluation and Management of Obese Patients. **2023**, 81, 490-504 ○
- 14 Antithrombotische Therapie. **2022**, 233-263 ○
- 13 Effect of direct thrombin inhibitors on laboratory measurement of fibrinogen: Potential for errors in clinical decision-making. ○
- 12 Direct Oral Anticoagulants: Laboratory Challenges and Antidotes. **2023**, 43, 037-043 ○

- 11 To Measure or Not to Measure: Direct Oral Anticoagulant Laboratory Assay Monitoring in Clinical Practice. **2023**, 2023, 1-7
- 10 Research Opportunities in Stroke Prevention for Atrial Fibrillation: A Report From a National Heart, Lung, and Blood Institute Virtual Workshop. **2023**, 54,
- 9 Generic Methods for Simultaneous Analysis of Four Direct Oral Anticoagulants in Human Plasma and Urine by Ultra-High Performance Liquid Chromatography-Tandem Mass Spectrometry. **2023**, 28, 2254
- 8 Direct Oral Anticoagulants: How Do These Drugs Work, How to Monitor, and What Is Their Role in Orthopaedic Surgery. **2023**, 31, e347-e355
- 7 Insights into the Pharmacokinetics and Pharmacodynamics of Direct Oral Anticoagulants in Older Adults with Atrial Fibrillation: A Structured Narrative Review. **2023**, 62, 351-373
- 6 Venous thromboembolism with renal infarct due to paradoxical embolism. **2023**, 16, e252322
- 5 Oral Anticoagulation in Patients With Advanced Chronic Kidney Disease and Atrial Fibrillation: Beyond Anticoagulation. **2023**,
- 4 Challenges of Anticoagulant Therapy in Atrial Fibrillation—Focus on Gastrointestinal Bleeding. **2023**, 24, 6879
- 3 Variability and Clinical Characteristics of Anti-factor Xa Activity Treated with Rivaroxaban in Chinese Patients Aged ≥80 years: A Single-center Study.
- 2 Clinical characteristics of patients with direct oral anticoagulant (DOAC) levels outside expected ranges: A retrospective chart study. **2023**, 100139
- 1 Assessment of delayed bleeding after endoscopic submucosal dissection of early-stage gastrointestinal tumors in patients receiving direct oral anticoagulants. 29, 2916-2931